Skip to main content
. 2015 Jan 10;43(3):1345–1356. doi: 10.1093/nar/gku1392

Table 1. Number of analyzed paired and unpaired tumor samples from each cancer type: breast carcinoma (BRCA), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear-cell carcinoma (KIRC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD) and thyroid carcinoma (THCA).

TCGA acronym Cancer type Paired samples Unpaired tumor samples Reference
BRCA Breast invasive carcinoma 107 929 (3)
COAD Colon adenocarcinoma 26 236 (1)
HNSC Head/neck squamous cell carcinoma 38 384 (27)
KICH Kidney chromophobe 21 41 https://tcga-data.nci.nih.gov/
KIRC Kidney renal clear cell carcinoma 71 434 (4)
LUAD Lung adenocarcinoma 57 431 (28)
LUSC Lung squamous cell carcinoma 50 433 (2)
PRAD Prostate adenocarcinoma 48 247 https://tcga-data.nci.nih.gov/
THCA Thyroid carcinoma 58 439 https://tcga-data.nci.nih.gov/

All data sets were obtained from https://tcga-data.nci.nih.gov/. For the paired samples we also used the corresponding normal samples from the same patients. For the list of samples used see Supplementary File S1.